In NSCLC, Xu and colleagues demonstrated that FOXC1 knockdown reduced CD133+ cell percentage, suppressed self-renewal ability, decreased expression of stemness-related genes (OCT4, NANOG, SOX2 and ABCG2) and inhibited NSCLC cell tumorigenicity in vivo (56). This evidence concerns the gene SOX2 and non-small cell lung carcinoma.